DataMeds AI enters IP license agreement with Reboot Health AI
MEDS•DataMeds AI entered an IP license agreement with Reboot Health AI on Oct. 13. Reboot granted an exclusive U.S. license to patents and a health AI platform, and will receive a portion of adjusted gross revenue, 666,667 shares and $50,000; reconfiguration is estimated to cost at least $100,000.
1. License terms
DataMeds AI entered an IP license agreement with Reboot Health AI on Oct. 13, according to an SEC filing. Reboot granted DataMeds an exclusive U.S. license to patents and a health AI platform. Reboot will receive a portion of DataMeds AI's adjusted gross revenue, 666,667 shares and $50,000; reconfiguration is estimated to cost at least $100,000.
